Evotec SE ADR (EVO)vsEli Lilly and Company (LLY)
EVO
Evotec SE ADR
$1.32
-8.97%
HEALTHCARE · Cap: $600.61M
LLY
Eli Lilly and Company
$1,347.11
-0.30%
HEALTHCARE · Cap: $1.27T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 11937% more annual revenue ($86.46B vs $718.32M). LLY leads profitability with a 31.9% profit margin vs -25.2%. LLY appears more attractively valued with a PEG of 1.33. LLY earns a higher WallStSmart Score of 74/100 (B).
EVO
Hold42
out of 100
Grade: D
LLY
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.5%
Fair Value
$33.26
Current Price
$1.32
$31.94 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 68 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 51.2%
Revenue surging 38.6% year-over-year
Generating 8.2B in free cash flow
Areas to Watch
0.6% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -28.6% — below average capital efficiency
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 29.8x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : EVO
The strongest argument for EVO centers on Price/Book. PEG of 1.42 suggests the stock is reasonably priced for its growth.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 51.2%. Revenue growth of 38.6% demonstrates continued momentum.
Bear Case : EVO
The primary concerns for EVO are Revenue Growth, EPS Growth, Market Cap.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.3x leaves little room for execution misses.
Key Dynamics to Monitor
EVO profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
EVO carries more volatility with a beta of 1.31 — expect wider price swings.
LLY is growing revenue faster at 38.6% — sustainability is the question.
LLY generates stronger free cash flow (8.2B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (74/100 vs 42/100), backed by strong 31.9% margins and 38.6% revenue growth. EVO offers better value entry with a 89.5% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Evotec SE ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Evotec SE is a prominent global biotechnology company headquartered in Hamburg, Germany, specializing in delivering comprehensive drug discovery and development solutions to the pharmaceutical and biotech industries. The firm is distinguished by its collaborative strategy, forming partnerships with leading pharmaceutical entities and prestigious academic institutions to accelerate the progress of a diverse range of therapeutic programs, including small molecules, biologics, and cell therapies. With a strong and growing pipeline, Evotec is strategically positioned to leverage new opportunities within the biopharmaceutical sector, reaffirming its essential contribution to healthcare innovation and improved patient outcomes.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?